• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

JDRF tackles insulin consistency, potency at U.S. pharmacies

April 11, 2018 By Sarah Faulkner

diabetesJDRF is teaming up with the American Diabetes Association and the Leona M. and Harry B. Helmsley Charitable Trust to support research evaluating the consistency and potency of insulin purchased at retail pharmacies in the U.S.

The group called for proposals from analytical laboratories to assess the activity of insulin in vials and cartridges, looking for variations that could pose a safety risk for people with diabetes.

The group’s efforts were spurred on by a study published last year in the Journal of Diabetes Science and Technology, in which researchers examined 18 vials of insulin produced by two different manufacturers. They reported an average insulin dosage of 40.2 U/mL with levels between 13.9 to 94.2 U/mL. None of the vials examined by the researchers met the FDA’s 95 U/mL standard.

Applicants hoping to win financial support from JDRF, ADA and the Helmsley trust should submit their full proposal by April 18, the group said. Research is expected to begin in July.

“As critical as insulin is to millions of Americans, JDRF believes further study is needed to analyze the quality of insulin at the point of sale and convened our close partners to investigate what has generated understandable concern in our community,” JDRF’s chief mission officer Aaron Kowalski said in prepared remarks. “At the same time, we want to stress that all people with Type I diabetes should continue to take insulin as prescribed.”

“Insulin is essential to the survival of millions of Americans with diabetes, and they should not have to worry about the quality of the insulin they must take every day. We concur that our proposed study is critical in allaying the serious concerns raised by Carter and Heinemann’s insulin potency study,” ADA’s chief scientific, medical & mission officer Dr. William Cefalu added.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Research & Development Tagged With: americandiabetesassociation, Juvenile Diabetes Research Foundation (JDRF)

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS